Subscribe to Newsletter
Subspecialties Retina

Oraya Therapy: One-year Outcomes

Oraya Therapy™ Stereotactic Radiotherapy for Wet AMD uses low-energy, highly targeted X-rays to treat wet AMD and is intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections. Full 2-year results from Oraya's INTREPID study were published in Ophthalmology, January 2015, and real world patient outcomes from three countries were present at EURETINA 15th Congress, September 2015. The Oraya Therapy is available in several treatment centres across Germany, Switzerland, and the United Kingdom.

http://www.orayainc.com/amd-clinical-outcomes/

http://www.orayainc.com

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: